Dimeric l-Dopa Derivatives as Potential Prodrugs

https://doi.org/10.1016/S0960-894X(01)00140-8Get rights and content

Abstract

A series of dimeric derivatives (+)-1, and (+)-2, and (+)-3a–d of l-Dopa diacetyl esters was synthesized and evaluated as potential l-Dopa prodrugs with improved physicochemical properties. All the new compounds showed chemical stability in aqueous buffer solutions (pH 1.3 and 7.4). A relatively slow release of l-Dopa in human plasma was observed.

A series of dimeric derivatives (+)-1, (+)-2, and (+)-3a–d of l-Dopa diacetyl esters was synthesized and evaluated as potential prodrugs with improved physicochemical properties. A relatively slow release of l-Dopa in human plasma was observed.

  1. Download : Download full-size image

Section snippets

Acknowledgements

This work was supported by the Ministero della Università e della Ricerca Scientifica e Tecnologica (Progetto Nazionale Tecnologie Farmaceutiche). The authors thank Prof. M. Cardellini for his collaboration and Mr. Domenico Rapposelli for his technical assistance.

References (14)

  • G.M Cingolani et al.

    Bioorg. Med. Chem. Lett.

    (2000)
  • J.A.M Christiaans et al.

    Eur. J. Pharm. Sci.

    (1996)
  • N.M Mahfouz et al.

    Eur. J. Med. Chem.

    (1998)
  • M Langlois et al.

    Eur. J. Med. Chem.

    (1994)
  • F Blandini et al.

    Drugs Today

    (1999)
  • N Bodor et al.

    J. Med. Chem.

    (1977)
  • D.R Cooper et al.

    J. Pharm. Pharmacol.

    (1987)
There are more references available in the full text version of this article.

Cited by (33)

  • Development of Prodrugs for Treatment of Parkinson‘s Disease: New Inorganic Scaffolds for Blood–Brain Barrier Permeation

    2022, Journal of Pharmaceutical Sciences
    Citation Excerpt :

    Dimeric L-DOPA acetylated derivatives (XXXVIII): are one of the few examples of dimeric prodrugs of L-DOPA. Their lipophilicity and the rates of enzymatic and chemical hydrolysis were found to be in the suitable range for PD treatment.96 Further studies on oral bioavailability have not been published yet.

  • L-dopa co-drugs in nanostructured lipid carriers: A comparative study

    2017, Materials Science and Engineering C
    Citation Excerpt :

    These multifunctional co-drugs could represent useful dopaminergic agents devoid of the pro-oxidant effects associated with the presence of the catechol moiety [13]. Finally, PDD, prepared by coupling reaction between 3,4-diacetyloxy-l-phenylalanine methyl ester hydrochloride with hexanedioyl dichloride, showed chemical stability in aqueous, acid, and physiological solutions [14]. However, all LD co-drugs, reported in this study, showed poor water solubility.

  • Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug

    2011, International Journal of Pharmaceutics
    Citation Excerpt :

    The current chemotherapy is essentially symptomatic using exogenous l-Dopa (LD), the direct precursor of DA, as drug (Blandini and Greenamyre, 1999; Andersen, 2004; Fahn, 2006). LD administration is however associated with three important problems: (i) LD metabolism generates a variety of cytotoxic reactive oxygen species (ROS) that contribute to the progression of the disease; (ii) LD has a poor bioavailability in the CNS; (iii) during chronic treatment, patients become sensitive to LD plasma level fluctuations (Dauer and Przedborski, 2003; Bindoli et al., 1992; Di Stefano et al., 2001). In order to overcome these problems, a multifunctional prodrug (LD–LA, Fig. 1) containing LD and natural lipoic acid moiety (LA) has been recently synthesized (Di Stefano et al., 2006).

View all citing articles on Scopus
View full text